FDA Enforcement Priorities Include Guidance On Detailing And Kickbacks
Executive Summary
FDA plans to weigh in on some of the pharmaceutical sales practices identified as problematic by the HHS Inspector General, FDA Commissioner McClellan indicated during an address to the National Press Club in Washington, D.C. Aug. 8